NIH R01 · 2025
Engineered cells as agents of arthritis therapy governed by artificial signaling
Project Summary Osteoarthritis (OA), a leading cause of years lost to disability worldwide, is characterized by the breakdown of the collagen II-rich matrix of articular cartilage, infiltration of immune cells, and inflammation of joint tissues such as the synovium. Because no disease-modifying drugs exist to treat arthritis, surgery is the eventual result for patients with progressive OA. Though current biologic therapies for treating OA offer some clinical benefit, outcomes deteriorate over time due to the inability of these approaches to induce robust, sustained regeneration of cartilage and stabilization of joint tissues. Investigational cell engineering strategies have been developed…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.